Value Set OID: 2.16.840.1.113883.3.464.1003.101.12.1012
Nursing Facility Visit
Measure | Description |
---|---|
CMS122v10 | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
CMS122v8 | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
CMS122v9 | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
CMS125v10 | Breast Cancer Screening |
CMS125v8 | Breast Cancer Screening |
CMS125v9 | Breast Cancer Screening |
CMS127v10 | Pneumococcal Vaccination Status for Older Adults |
CMS127v11 | Pneumococcal Vaccination Status for Older Adults |
CMS127v7 | Pneumococcal Vaccination Status for Older Adults |
CMS127v8 | Pneumococcal Vaccination Status for Older Adults |
CMS127v9 | Pneumococcal Vaccination Status for Older Adults |
CMS128v10 | Anti-depressant Medication Management |
CMS128v11 | Anti-Depressant Medication Management |
CMS128v12 | Anti-depressant Medication Management |
CMS128v8 | Anti-depressant Medication Management |
CMS128v9 | Anti-depressant Medication Management |
CMS130v10 | Colorectal Cancer Screening |
CMS130v8 | Colorectal Cancer Screening |
CMS130v9 | Colorectal Cancer Screening |
CMS131v10 | Diabetes: Eye Exam |
CMS131v8 | Diabetes: Eye Exam |
CMS131v9 | Diabetes: Eye Exam |
CMS134v10 | Diabetes: Medical Attention for Nephropathy |
CMS134v8 | Diabetes: Medical Attention for Nephropathy |
CMS134v9 | Diabetes: Medical Attention for Nephropathy |
CMS135v10 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v11 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v12 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v5 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v6 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v7 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v8 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS135v9 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS139v10 | Falls: Screening for Future Fall Risk |
CMS139v11 | Falls: Screening for Future Fall Risk |
CMS139v12 | Falls: Screening for Future Fall Risk |
CMS139v5 | Falls: Screening for Future Fall Risk |
CMS139v6 | Falls: Screening for Future Fall Risk |
CMS139v7 | Falls: Screening for Future Fall Risk |
CMS139v8 | Falls: Screening for Future Fall Risk |
CMS139v9 | Falls: Screening for Future Fall Risk |
CMS142v10 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v11 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v12 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v5 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v6 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v7 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v8 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS142v9 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
CMS143v10 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v11 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v12 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v5 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v6 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v7 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v8 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS143v9 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
CMS144v10 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v11 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v12 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v5 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v6 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v7 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v8 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS144v9 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
CMS145v10 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v11 | Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ? 40%) |
CMS145v12 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <=40%) |
CMS145v5 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v6 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v7 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v8 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS145v9 | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
CMS147v10 | Preventive Care and Screening: Influenza Immunization |
CMS147v11 | Preventive Care and Screening: Influenza Immunization |
CMS147v12 | Preventive Care and Screening: Influenza Immunization |
CMS147v6 | Preventive Care and Screening: Influenza Immunization |
CMS147v7 | Preventive Care and Screening: Influenza Immunization |
CMS147v8 | Preventive Care and Screening: Influenza Immunization |
CMS147v9 | Preventive Care and Screening: Influenza Immunization |
CMS149v10 | Dementia: Cognitive Assessment |
CMS149v11 | Dementia: Cognitive Assessment |
CMS149v12 | Dementia: Cognitive Assessment |
CMS149v5 | Dementia: Cognitive Assessment |
CMS149v6 | Dementia: Cognitive Assessment |
CMS149v7 | Dementia: Cognitive Assessment |
CMS149v8 | Dementia: Cognitive Assessment |
CMS156v10 | Use of High-Risk Medications in Older Adults |
CMS156v11 | Use of High-Risk Medications in Older Adults |
CMS156v12 | Use of High-Risk Medications in Older Adults |
CMS156v7 | Use of High-Risk Medications in the Elderly |
CMS156v8 | Use of High-Risk Medications in the Elderly |
CMS156v9 | Use of High-Risk Medications in Older Adults |
CMS165v10 | Controlling High Blood Pressure |
CMS165v8 | Controlling High Blood Pressure |
CMS165v9 | Controlling High Blood Pressure |
CMS167v5 | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy |
CMS167v6 | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy |
MedicalCodify.com